Mouse VEGFR1/Flt-1 PE-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # FAB4711P
Key Product Details
Validated by
Species Reactivity
Validated:
Cited:
Applications
Validated:
Cited:
Label
Antibody Source
Product Specifications
Immunogen
Ser27-Glu759
Accession # P35969
Specificity
Clonality
Host
Isotype
Scientific Data Images for Mouse VEGFR1/Flt-1 PE-conjugated Antibody
Detection of VEGF R1/Flt‑1 in bEnd.3 Mouse Cell Line by Flow Cytometry.
bEnd.3 mouse endothelioma cell line was stained with Rat Anti-Mouse VEGF R1/Flt-1 PE-conjugated Monoclonal Antibody (Catalog # FAB4711P, filled histogram) or isotype control antibody (Catalog # IC013P, open histogram). View our protocol for Staining Membrane-associated Proteins.Detection of Mouse VEGFR1/Flt-1 by Flow Cytometry
Fibroblast-derived VEGF enriches VEGFR1+ cells bone marrow and pre-metastatic sites.(a) Immunohistochemical expression of mouse VEGF in the tumour xenografts established with KYSE150-Id1, KYSE150-Id1-shIGF2 or vector control cells (scale bar, 20 μm). (b) Flow cytometry data showing the expression of VEGFR1+ cells in bone marrow (upper panel) and lungs (lower panel) of mice with subcutaneous implantation of indicated fibroblasts and treatment (female 6–8-week-old nude mice, n=3 per group). (c,d) Flow cytometry analysis of VEGFR1+ cells (c) and comparison of tumour volume (d) of subcutaneous tumour xenografts established from co-implantation of KYSE150 cells and indicated NEFs in the presence or absence of Avastin treatment. Photographs show representative tumours of the three groups (female 6–8-week-old nude mice, n=6 per group; scale bar, 1 cm). Bars, s.d.; *P<0.05; **P<0.01; ***P<0.001 by Student's t-test. Image collected and cropped by CiteAb from the following publication (https://www.nature.com/articles/ncomms14399), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of Mouse VEGFR1/Flt-1 by Flow Cytometry
Fibroblast-derived VEGF enriches VEGFR1+ cells bone marrow and pre-metastatic sites.(a) Immunohistochemical expression of mouse VEGF in the tumour xenografts established with KYSE150-Id1, KYSE150-Id1-shIGF2 or vector control cells (scale bar, 20 μm). (b) Flow cytometry data showing the expression of VEGFR1+ cells in bone marrow (upper panel) and lungs (lower panel) of mice with subcutaneous implantation of indicated fibroblasts and treatment (female 6–8-week-old nude mice, n=3 per group). (c,d) Flow cytometry analysis of VEGFR1+ cells (c) and comparison of tumour volume (d) of subcutaneous tumour xenografts established from co-implantation of KYSE150 cells and indicated NEFs in the presence or absence of Avastin treatment. Photographs show representative tumours of the three groups (female 6–8-week-old nude mice, n=6 per group; scale bar, 1 cm). Bars, s.d.; *P<0.05; **P<0.01; ***P<0.001 by Student's t-test. Image collected and cropped by CiteAb from the following publication (https://www.nature.com/articles/ncomms14399), licensed under a CC-BY license. Not internally tested by R&D Systems.Applications for Mouse VEGFR1/Flt-1 PE-conjugated Antibody
Flow Cytometry
Sample: bEnd.3 mouse endothelioma cell line
Reviewed Applications
Read 2 reviews rated 4.5 using FAB4711P in the following applications:
Formulation, Preparation, and Storage
Purification
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, 2 to 8 °C as supplied.
Background: VEGFR1/Flt-1
VEGF R1 is one of the five receptor tyrosine kinases (RTKs) (VEGF R1, KDR/Flk-1, Flt-4, Tie-1, and Tek/Tie-2) whose expression is almost exclusively restricted to the endothelial cells. Tie-1 and tek/tie-2 define a new class of RTKs containing two immunoglobulin-like domains, three EGF homology domains and three fibronectin type III domains in their extracellular regions. VEGF R1/Flt-1, VEGF R2/KDR/Flk-1, VEGF R3/Flt-4 are members of the class III subfamily of RTKs containing seven immunoglobulin-like repeats in their extracellular domains. All five RTKs are likely to play central roles in vasculogenesis and angiogenesis.
Full length mouse VEGF R1 mRNA encodes a 1333 amino acid (aa) residue precursor with a predicted 22 aa residue signal peptide. Mature VEGF R1 is composed of a 737 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 552 aa residue cytoplasmic domain. As a result of alternative splicing of the mRNA, a cDNA encoding a truncated form of VEGF R1, lacking the seventh immunoglobulin-like domain, the transmembrane and intracellular domains, has been cloned. The recombinant soluble VEGF R1/Fc chimera binds VEGF and PlGF with high affinity and is a potent VEGF antagonist.
References
- He, Y. et al. (1999) Molecular Endocrinology 13:537.
- Ferrara, N. and T. Davis-Smyth (1997) Endocrine Reviews 8:4.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional VEGFR1/Flt-1 Products
Product Documents for Mouse VEGFR1/Flt-1 PE-conjugated Antibody
Product Specific Notices for Mouse VEGFR1/Flt-1 PE-conjugated Antibody
For research use only